文献速递免疫规划

棘突蛋白重组N端结构域是抗中东呼吸综合征冠状病毒感染的潜在疫苗

The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
PubMed 文献 · Vaccine · 2016-11-26

本研究探讨棘突蛋白重组N端结构域(rNTD)作为中东呼吸综合征冠状病毒(MERS-CoV)疫苗候选物的免疫原性与保护潜力。BALB/c小鼠接种5或10μg rNTD蛋白后产生显著体液免疫应答(血清IgG和中和活性);10μg rNTD结合铝佐剂和CpG佐剂诱导显著功能性T细胞免疫。rNTD免疫小鼠在表达人DPP4的腺病毒载体转染MERS-CoV攻击小鼠模型中肺部病变减轻,保护效果与rRBD疫苗接种一致。

要点

  • 5或10μg rNTD蛋白接种BALB/c小鼠诱导显著血清IgG和中和活性体液免疫应答。
  • 10μg rNTD结合铝佐剂和CpG佐剂诱导显著功能性T细胞免疫。
  • rNTD免疫小鼠在MERS-CoV攻击模型中肺部病变减轻,保护效果与rRBD疫苗接种一致。

核心结论

  • rNTD在小鼠中诱导强效细胞免疫和抗原特异性中和抗体,并显示针对病毒攻击的保护能力,表明rNTD是抗MERS-CoV感染的疫苗候选物。

研究设计与样本

  • 研究使用BALB/c小鼠评估重组N端结构域(rNTD)的免疫原性和保护潜力,并以rRBD疫苗接种作为保护效果对照。

主要发现

  • BALB/c小鼠接种5或10μg rNTD蛋白后诱导显著体液免疫应答(血清IgG和中和活性)。
  • 10μg rNTD结合铝佐剂和CpG佐剂接种诱导显著且功能性T细胞免疫(酶联免疫斑点、细胞内细胞因子染色和 cytometric bead array 检测)。
  • rNTD免疫小鼠在转染表达人DPP4腺病毒载体的MERS-CoV攻击小鼠模型中肺部病变减轻,保护效果与rRBD疫苗接种一致。

关键数值与推荐

  • 5或10μg rNTD蛋白接种BALB/c小鼠后血清IgG和中和活性显著。
  • 10μg rNTD结合铝佐剂和CpG佐剂诱导显著功能性T细胞免疫。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The persistent public health threat of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) highlights the need for an effective MERS-CoV vaccine. Previous studies have focused mainly on the receptor-binding domain (RBD) on the spike protein of MERS-CoV. Herein, we investigated the immunogenicity and protective potential of the recombinant N-terminal domain (rNTD) of spike proteins as a vaccine candidate. BALB/c mice vaccinated with 5 or 10μg of rNTD protein demonstrated a significant humoral immune response (serum IgG and neutralizing activity). Additionally, according to the enzyme-linked immunospot, intracellular cytokine staining, and cytometric bead array assays, significant and functional T-cell immunity was induced by 10μg of the rNTD vaccination with aluminum and CpG adjuvant. Furthermore, rNTD-immunized mice showed reduced lung abnormalities in a MERS-CoV-challenge mouse model transfected with an adenoviral vector expressing human DPP4, showing protection consistent with that found with rRBD vaccination. These data show that rNTD induced potent cellular immunity and antigen-specific neutralizing antibodies in mice and that it demonstrated protective capacity against a viral challenge, indicating that rNTD is a vaccine candidate against MERS-CoV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jiaming L, Yanfeng Y, Yao D, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2016. PMID: 27899228. doi:10.1016/j.vaccine.2016.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。